The clearest signal in years from U.S. newborn data is also one of the simplest to act on: skipping the intramuscular vitamin K shot at birth is linked to more infant bleeding, and especially more dangerous brain bleeds, in the months that follow.
At a Glance
- Across a national cohort of 5.2 million infants, nonreceipt of vitamin K was associated with higher bleeding by six months of age, with the strongest excess risk seen for intracranial hemorrhage.
- Refusal has more than doubled in recent years; fewer babies receive the one-time shot today than a decade ago.
- The pattern is consistent across multiple large datasets and with earlier observational research, pointing in the same direction and magnitude.
- Mechanistically the link is straightforward: newborns start life vitamin K–deficient, impairing production of clotting factors; intramuscular vitamin K corrects that deficit quickly and reliably.
What the new evidence actually shows
In the largest analysis to date, investigators using de-identified electronic health records followed 5.2 million U.S. infants and compared bleeding outcomes through six months between those who received intramuscular vitamin K at birth and those who did not. The nonrecipient group had higher rates of “any bleeding” and a markedly higher rate of intracranial hemorrhage. For brain bleeds in particular, the adjusted relative risk was 2.43 (95% CI, 2.26–2.62) — more than double — with absolute rates reported as 33.0 versus 13.2 per 10,000 births. A companion communication translated the all-bleeding comparison to plain terms: roughly 2.9% of nonrecipients had a bleeding event vs 1.9% of recipients, an approximately 47% relative increase.
This is not a single-study fluke. A separate JAMA Pediatrics analysis of over 11 million infants found that vitamin K supplementation declined from 2017 to 2025 while diagnoses of vitamin K deficiency and vitamin K–deficiency bleeding increased, a population-level alignment of exposure and outcome that matches clinical expectations. Earlier observational work has reported similar effect sizes for both any bleeding (adjusted odds near 1.5) and intracranial bleeding (near threefold), underscoring the stability of the finding across designs and eras.
Why vitamin K at birth prevents bleeding
The mechanism is direct biochemistry, not epidemiologic inference. Vitamin K is required to gamma-carboxylate coagulation factors II, VII, IX, and X; without adequate vitamin K, those factors are synthesized but function poorly. Newborns begin life with limited vitamin K stores because placental transfer is minimal, intestinal flora that synthesize vitamin K are not yet established, and breast milk contains low levels. The one-time intramuscular dose at birth supplies sufficient vitamin K to enable normal clotting while endogenous sources come online. That is why the American Academy of Pediatrics has recommended routine IM vitamin K prophylaxis since 1961, and why the United States adopted it widely in the 1960s.
Clinical syndromes reflect timing and physiology. Early bleeding (first day) often involves oozing from procedural sites. Classic bleeding (first week) may present with gastrointestinal or cutaneous bleeding. Late bleeding (weeks to months), which is more strongly linked to nonreceipt and exclusive breastfeeding without supplementation, disproportionately affects the brain — exactly where the new data show the largest risk gradient.
How we arrived here: from routine success to renewed refusal
Preventive medicine has a paradox: when it works, the harm it prevents disappears from view, inviting doubt about whether the intervention is necessary. Vitamin K is a textbook example. For decades, near-universal acceptance kept vitamin K–deficiency bleeding rare. Over the past several years, however, nonreceipt has climbed: in the 5.2‑million‑infant cohort, documented nonreceipt rose from 3.1% in 2017 to 6.8% in 2025. The larger database analysis likewise documented declining administration alongside rising deficiency and bleeding diagnoses.
Clinically, many refusals are bundled with a preference to “avoid interventions” in the first hours of life or confusion that vitamin K is a vaccine — it is not. The dose is a vitamin given intramuscularly, not an immunization; its purpose is to restore a known physiologic deficit. The renewed rise in refusal therefore brings a familiar communication challenge: explaining small absolute risks with large consequences, and why a one-time shot meaningfully shifts those odds.
How strong is the evidence — and what are its limits?
These are observational datasets, not randomized trials. As such, they establish robust associations, not individual-level causation for every single case. That said, three features make the inference compelling. First, the biological mechanism is settled. Second, the risk gradients are specific and proportionate — especially for intracranial hemorrhage, where the adjusted risk more than doubles. Third, triangulation across independent, very large cohorts points in the same direction with similar magnitudes. Those converging lines of evidence are what clinicians rely on when trials are impractical or unethical.
Two cautions keep the discussion honest without blunting the take‑home message. Electronic‑record platforms like Epic Cosmos may underrepresent some births or misclassify exposure, and “any bleeding” aggregates mild and severe events. Neither caveat erases the core signal, and the severe endpoint — brain bleeding — is precisely where the strongest, clinically decisive difference appears.
An 11-day-old baby reportedly suffered hours of uncontrolled bleeding while waiting for a critical Vitamin K shot in the ER. A heartbreaking case raising serious questions about newborn care and emergency response. 💔
Read more: https://t.co/qwSL8efIvj#NewbornHealth #VitaminK pic.twitter.com/FLyBwsT8up
— Olivia Ross (@OliviaRoss70) November 10, 2026
Clinical and parental decision-making: translating risk into practice
For families, the question is simple but weighty: what changes for my baby if we accept or refuse the shot? The best current evidence says that accepting intramuscular vitamin K reduces the likelihood of any clinically coded bleeding in the first six months and more than halves the risk of a brain bleed — an uncommon event with life‑altering stakes if it occurs. For hospitals and pediatric practices, the practical response is equally clear: normalize informed consent prenatally, distinguish vitamins from vaccines in language and materials, and ensure that the default is timely IM administration shortly after birth. Where oral regimens are discussed, clinicians should be explicit about adherence demands and the weaker protection they provide relative to IM dosing, especially against late intracranial hemorrhage — the outcome parents fear most.
What the trend means going forward
Rising refusal has reversed part of a half‑century public‑health success. If the trajectory continues, more infants will experience preventable bleeding and more families will confront neurosurgical decisions that a one‑time shot could have made far less likely. The remedy is not complicated: sustained, respectful communication anchored in the mechanism and the numbers, delivered before delivery, and backed by consistent clinical practice. That is how routine, high‑value prevention regains its footing — not by rhetoric, but by clarity about risk and benefit, presented when decisions are still open.
Sources:
washingtontimes.com, inquirer.com, jamanetwork.com, clinicalfutures.research.chop.edu, detroitnews.com
